Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma Journal Article
| Authors: | Teo, M. Y.; Rosenberg, J. E. |
| Article Title: | Perioperative immunotherapy in muscle-invasive bladder cancer and upper tract urothelial carcinoma |
| Abstract: | Neoadjuvant chemotherapy improves survival in patients with muscle-invasive bladder cancer. However, a significant proportion of patients are ineligible for cisplatin owing to renal impairment or other medical comorbidities. The introduction of anti-programmed cell death protein 1/programmed death-ligand 1(PD1/PD-L1) checkpoint inhibitors has redefined the therapeutic landscape for platinum-resistant urothelial cancers; their clinical efficacy and favorable toxicity render these agents attractive therapeutic options either as monotherapy or in combination with other agents in earlier disease states, including muscle-invasive disease. We review potential perioperative immunotherapy strategies, ongoing clinical trials and areas of unmet needs, including upper tract disease and non-urothelial cancers. © 2018 Elsevier Inc. |
| Keywords: | cancer chemotherapy; overall survival; review; cisplatin; placebo; drug efficacy; drug safety; multimodality cancer therapy; gemcitabine; paclitaxel; combined modality therapy; neoadjuvant therapy; ipilimumab; cancer immunotherapy; pathology; bladder tumor; urinary bladder neoplasms; kidney neoplasms; docetaxel; immunology; immunotherapy; kidney tumor; drug response; urothelial carcinoma; ureteral neoplasms; neoadjuvant chemotherapy; platinum complex; taxane derivative; carcinoma, transitional cell; transitional cell carcinoma; pemetrexed; urinary tract; ureter tumor; vinflunine; programmed death 1 ligand 1; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); pd-l1; muscle invasive bladder cancer; muscle-invasive bladder cancer; nivolumab; humans; human; priority journal; pembrolizumab; antagonists and inhibitors; atezolizumab; immunological antineoplastic agent; antineoplastic agents, immunological; pd1; renal pelvis urothelial carcinoma; ureteral carcinoma; b7-h1 antigen |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 45 |
| Issue: | 2 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2018-05-01 |
| Start Page: | 287 |
| End Page: | 295 |
| Language: | English |
| DOI: | 10.1016/j.ucl.2017.12.011 |
| PUBMED: | 29650143 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 May 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work